**1. Introduction**

Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) describes a group of diseases that are characterized by hepatic steatosis without the excessive intake of alcohol. NAFLD/NASH may involve cirrhosis and/or hepatocellular carcinoma (HCC). NAFLD may be differentiated from the more benign state of the nonalcoholic liver to nonalcoholic steatohepatitis (NASH), which is the most serious manifestation of the disease. In the first case, hepatic steatosis presents without indication of inflammation, while in NASH hepatic steatosis is connected to lobular inflammation and apoptosis that may lead to fibrosis and cirrhosis [1] (**Figure 1**). Therapeutic management is divided into two kinds of measures: Lifestyle intervention and pharmacological/surgical treatment.

**Figure 1.** *NAFLD-NASH staging and progression.*
